The federal government and states will face a number of challenges upon establishing and operating federally facilitated health insurance exchanges.
The federal government and states will face challenges in establishing and operating federally facilitated health insurance exchanges, according to a new Health Policy Brief from Health Affairs and the Robert Wood Johnson Foundation. Federal exchanges will be implemented in the 25 states that have elected to forgo running their own exchanges, as well as states that have decided to create and operate an exchange in partnership with the federal government.
One obstacle is the variation in state laws. It will be challenging for the Department of Health and Human Services (HHS) to customize exchanges to meet each state’s unique market needs, the policy brief says.
There is also an issue with states deciding not to expand Medicaid coverage. Without an expansion, people with incomes between 100% and 138% of the federal poverty level will be eligible to purchase coverage through exchanges, however those under 138%, who would have qualified for Medicaid with expansion, will not recieve subsidies because the law did not account for the possiblity of a state opt-out. Subsidized private coverage through an exchange will most likely cost more than Medicaid coverage, so the overall federal cost will be higher.
Additionally, the federal government will only be able to regulate plans that are sold through the exchanges, which is also potentially problematic. It runs the risk of healthy people opting for cheaper plans outside the exchange, while “sicker” people opt for exchange coverage. This increases the risk for adverse selection. Although there are risk-adjustment aspects to the Patient Protection and Affordable Care Act that could alleviate a plan’s gains and losses, they may not take effect right off the bat.
The timetable for the planning and implementation of these exchanges is also constricted. All exchanges must be ready for open enrollment, scheduled for October 2013, in order to be ready for the plan year that starts Jan. 1, 2014.
HHS has allowed states until the end of 2014 to obtain and use exchange establishment funding from the federal government, and it’s possible some states that initially decided to pass up creating their own exchange for an exchange partnership or federally facilitated model may replace those with an entirely state-run exchange.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More